Maria Corinna Palanca-Wessels
University of Washington
H-index: 23
North America-United States
Top articles of Maria Corinna Palanca-Wessels
Abstract CT078: Phase 1 study of SGN-EGFRd2 in solid tumors (SGNEGFRd2-001)
Cancer Research
2024/4/5
SGN-EGFRd2 binding and activity are agnostic to common EGFR extracellular resistance mutations acquired in response to anti-EGFR targeted antibody therapies
Cancer Research
2024/3/22
Liem Nguyen
H-Index: 29
Maria Corinna Palanca-Wessels
H-Index: 16
Humanized anti-liv1 antibodies for the treatment of breast cancer
2024/3/7
Real-world treatment patterns in patients with HER2-amplified metastatic colorectal cancer: a clinical-genomic database study
Journal of the National Comprehensive Cancer Network
2023/8/1
MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in …
2022/1/5
Heinz-Josef Lenz
H-Index: 72
Salvatore Siena
H-Index: 66
Maria Corinna Palanca-Wessels
H-Index: 16
John Marshall
H-Index: 3
1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction …
Annals of Oncology
2021/9/1
439P Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study
Annals of Oncology
2021/9/1
P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma …
Annals of Oncology
2021/7/1
PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
Annals of Oncology
2021/7/1
PCN157 Characteristics and Treatment Patterns Among Patients Diagnosed with Metastatic Colorectal Cancer in the United States: A Healthcare Claims Database Analysis
Value in Health
2021/6/1
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
European Journal of Cancer
2021/5/1
MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial …
2021/1/20
Heinz-Josef Lenz
H-Index: 72
Salvatore Siena
H-Index: 66
Maria Corinna Palanca-Wessels
H-Index: 16
John Marshall
H-Index: 3
MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
2021/1/20
Salvatore Siena
H-Index: 66
Maria Corinna Palanca-Wessels
H-Index: 16
Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without …
Cancer Research
2020/2/15
Rashmi Murthy
H-Index: 4
Elisavet Paplomata
H-Index: 10
Nancy Lin
H-Index: 54
Virginia Borges
H-Index: 35
Francois P Duhoux
H-Index: 15
David Cameron
H-Index: 25
Maria Corinna Palanca-Wessels
H-Index: 16
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
New England Journal of Medicine
2020/2/13
Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases …
Cancer research
2020/2/1
Rashmi Murthy
H-Index: 4
Elisavet Paplomata
H-Index: 10
Nancy Lin
H-Index: 54
Virginia Borges
H-Index: 35
Francois P Duhoux
H-Index: 15
David Cameron
H-Index: 25
Maria Corinna Palanca-Wessels
H-Index: 16
Co-Authors
